Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK.

Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013. Epub 2018 Aug 16.

2.

Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Chen Y, Xue SA, Behboudi S, Mohammad GH, Pereira SP, Morris EC.

Clin Cancer Res. 2017 Oct 15;23(20):6178-6189. doi: 10.1158/1078-0432.CCR-17-1185. Epub 2017 Jul 14.

3.

An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.

Knies D, Klobuch S, Xue SA, Birtel M, Echchannaoui H, Yildiz O, Omokoko T, Guillaume P, Romero P, Stauss H, Sahin U, Herr W, Theobald M, Thomas S, Voss RH.

Oncotarget. 2016 Apr 19;7(16):21199-221. doi: 10.18632/oncotarget.8385.

4.

Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy.

Holler A, Zech M, Ghorashian S, Pike R, Hotblack A, Veliça P, Xue SA, Chakraverty R, Morris EC, Stauss HJ.

Haematologica. 2016 Apr;101(4):482-90. doi: 10.3324/haematol.2015.132712. Epub 2016 Jan 22.

5.

CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.

Ghorashian S, Veliça P, Chua I, McNicol AM, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Xue SA, Uckert W, Morris E, Chakraverty R, Stauss HJ.

J Immunol. 2015 Feb 1;194(3):1080-9. doi: 10.4049/jimmunol.1401703. Epub 2014 Dec 24.

6.

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.

Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A.

J Hepatol. 2015 Feb;62(2):486-91. doi: 10.1016/j.jhep.2014.10.001. Epub 2014 Oct 13.

PMID:
25308176
7.

Adiponectin receptor signaling on dendritic cells blunts antitumor immunity.

Tan PH, Tyrrell HE, Gao L, Xu D, Quan J, Gill D, Rai L, Ding Y, Plant G, Chen Y, Xue JZ, Handa AI, Greenall MJ, Walsh K, Xue SA.

Cancer Res. 2014 Oct 15;74(20):5711-22. doi: 10.1158/0008-5472.CAN-13-1397. Epub 2014 Sep 26.

8.

Characteristics of TCM constitutions of adult Chinese women in Hong Kong and identification of related influencing factors: a cross-sectional survey.

Sun Y, Liu P, Zhao Y, Jia L, He Y, Xue SA, Zheng X, Wang Z, Wang N, Chen J.

J Transl Med. 2014 May 21;12:140. doi: 10.1186/1479-5876-12-140.

9.

Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.

Xue SA, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ.

Oncoimmunology. 2013 Jan 1;2(1):e22590.

10.

Acupuncture therapy on apoplectic aphasia rehabilitation.

Sun Y, Xue SA, Zuo Z.

J Tradit Chin Med. 2012 Sep;32(3):314-21. Review.

11.

Stuttering attitudes in Hong Kong and adjacent Mainland China.

Ip ML, St Louis KO, Myers FL, Xue SA.

Int J Speech Lang Pathol. 2012 Dec;14(6):543-56. doi: 10.3109/17549507.2012.712158. Epub 2012 Sep 14.

PMID:
22974072
12.

CD3 limits the efficacy of TCR gene therapy in vivo.

Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ.

Blood. 2011 Sep 29;118(13):3528-37. doi: 10.1182/blood-2011-04-346338. Epub 2011 Jul 12.

13.
14.

Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.

Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ.

Blood. 2011 Jul 14;118(2):319-29. doi: 10.1182/blood-2010-12-326736. Epub 2011 May 23.

15.

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.

Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S, Hasan F, Xue SA, Wilson N, Dalgleish A, Williams O, Anderson J.

Cancer Immunol Immunother. 2011 Sep;60(9):1243-55. doi: 10.1007/s00262-011-1024-4. Epub 2011 May 7.

PMID:
21553146
16.

Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination.

Pospori C, Xue SA, Holler A, Voisine C, Perro M, King J, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC.

Blood. 2011 Jun 23;117(25):6813-24. doi: 10.1182/blood-2010-08-304568. Epub 2011 Mar 29.

17.

Burkitt's lymphoma: maximising the use of fine needle aspirates by long-term preservation for diagnosis and research.

Van Noorden S, Lampert IA, Xue SA, Lykidis D, Phillips JA, Molyneux E, Griffin BE.

Trans R Soc Trop Med Hyg. 2011 Feb;105(2):86-94. doi: 10.1016/j.trstmh.2010.11.001. Epub 2010 Dec 18.

PMID:
21168891
18.

Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.

Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A.

J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23.

PMID:
21145860
19.

Analysis of propagation of multi-channel EEG in the test of sustained attention.

Nan Y, Wang J, Xue SA, Sheng H, Jiao Y, Wang J.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:1666-9. doi: 10.1109/IEMBS.2010.5626692.

PMID:
21096392
20.

Vocal tract dimensional development of adolescents: an acoustic reflection study.

Xue SA, Cheng RW, Ng LM.

Int J Pediatr Otorhinolaryngol. 2010 Aug;74(8):907-12. doi: 10.1016/j.ijporl.2010.05.010.

PMID:
20846502

Supplemental Content

Loading ...
Support Center